Loading...
•
Mar 31, 2023
Harrow Q1 2023 Earnings Report
Harrow announced strong first quarter results, demonstrating successful execution of its strategic plan.
Key Takeaways
Harrow reported record revenues of $26.1 million for Q1 2023, a 28% increase over the previous quarter. The company reaffirms its 2023 revenue guidance of $135 million to $143 million and adjusted EBITDA of $44 million to $50 million.
Harrow achieved record revenues of $26.1 million in Q1 2023.
Revenue increased by 28% compared to the fourth quarter of 2022.
The company expects branded pharmaceutical product revenue to outpace compounded pharmaceutical product revenue.
2023 revenue guidance is reaffirmed at $135 million to $143 million, with adjusted EBITDA between $44 million and $50 million.
Forward Guidance
Harrow reaffirms its 2023 revenue guidance of $135 million to $143 million and adjusted EBITDA of $44 million to $50 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...